Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20167603 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Guo X, Williams JG, Schug TT, Li X (2010) DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J Biol Chem 285, 13223-32 20167603
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

K382-a - p53 (human) ▲
Orthologous residues
p53 (human): K382‑a, p53 (mouse): K376‑a, p53 iso2 (mouse): ‑, p53 (rat): K380‑a, p53 (rabbit): K380‑a, p53 (monkey): K382‑a
Characterization
 Methods used to characterize site in vivo:  modification-specific antibody, western blotting
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
DEACETYLASE SIRT1 (mouse) inhibition of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase
DYRK1A (human) decrease DYRK1A siRNA leads to hyperacetylation of p53 K382
DYRK3 (human) decrease DYRK3 siRNA leads to hyperacetylation of p53 K382

T522-p - SIRT1 (mouse) ▲
Orthologous residues
SIRT1 (human): T530‑p, SIRT1 (mouse): T522‑p, SIRT1 (rat): T534‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), MEF (fibroblast), U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE DYRK1A (human)
KINASE DYRK3 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE DYRK3 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme
KINASE DYRK1A (human) siRNA inhibition of enzyme, transfection of wild-type enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heat shock increase
Downstream Regulation
 Effect of modification (function):  acetylation, enzymatic activity, induced, molecular association, regulation
 Effect of modification (process):  apoptosis, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
p53 (human) Disrupts pull-down assay
 Comments:  promotes cell survival


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.